Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Metastatic × abemaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 75 Neoplasm Metastasis 20 Brain Neoplasms 10 Prostatic Neoplasms 9 Neoplasms 9 Endometrial Neoplasms 9 Carcinoma, Non-Small-Cell Lung 8 Glioblastoma 7 Ovarian Neoplasms 6 Triple Negative Breast Neoplasms 5 Glioma 5 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Colorectal Neoplasms 4 Sarcoma, Ewing 3 Osteosarcoma 3 Multiple Myeloma 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Unilateral Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Neuroblastoma 2 Mesothelioma, Malignant 2 Melanoma 2 Lymphoma 2 Lung Neoplasms 2

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 Capecitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡